Literature DB >> 9643858

Fasting insulin and apolipoprotein B levels and low-density lipoprotein particle size as risk factors for ischemic heart disease.

B Lamarche1, A Tchernof, P Mauriège, B Cantin, G R Dagenais, P J Lupien, J P Després.   

Abstract

CONTEXT: Epidemiological studies have established a relationship between cholesterol and low-density lipoprotein cholesterol (LDL-C) concentrations and the risk of ischemic heart disease (IHD), but up to half of patients with IHD may have cholesterol levels in the normal range.
OBJECTIVE: To assess the ability to predict the risk of IHD using a cluster of nontraditional metabolic risk factors that includes elevated fasting insulin and apolipoprotein B levels as well as small, dense LDL particles.
DESIGN: Nested case-control study.
SETTING: Cases and controls were identified from the population-based cohort of the Quebec Cardiovascular Study, a prospective study conducted in men free of IHD in 1985 and followed up for 5 years. PARTICIPANTS: Incident IHD cases were matched with controls selected from among the sample of men who remained IHD free during follow-up. Matching variables were age, smoking habits, body mass index, and alcohol consumption. The sample included 85 complete pairs of nondiabetic IHD cases and controls. MAIN OUTCOME MEASURES: Ability of fasting insulin level, apolipoprotein B level, and LDL particle diameter to predict IHD events, defined as angina, coronary insufficiency, nonfatal myocardial infarction, and coronary death.
RESULTS: The risk of IHD was significantly increased in men who had elevated fasting plasma insulin and apolipoprotein B levels and small, dense LDL particles, compared with men who had normal levels for 2 of these 3 risk factors (odds ratio [OR], 5.9; 95% confidence interval [CI], 2.3-15.4). Multivariate adjustment for LDL-C, triglycerides, and high-density lipoprotein cholesterol (HDL-C) did not attenuate the relationship between the cluster of nontraditional risk factors and IHD (OR, 5.2; 95% CI, 1.7-15.7). On the other hand, the risk of IHD in men having a combination of elevated LDL-C and triglyceride levels and reduced HDL-C levels was no longer significant (OR, 1.4; 95% CI, 0.5-3.5) after multivariate adjustment for fasting plasma insulin level, apolipoprotein B level, and LDL particle size.
CONCLUSION: Results from this prospective study suggest that the measurement of fasting plasma insulin level, apolipoprotein B level, and LDL particle size may provide further information on the risk of IHD compared with the information provided by conventional lipid variables.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9643858     DOI: 10.1001/jama.279.24.1955

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  51 in total

1.  Abdominal obesity and the "hypertriglyceridaemic waist" phenotype.

Authors:  P Little; C D Byrne
Journal:  BMJ       Date:  2001-03-24

Review 2.  Lipoprotein changes with statins.

Authors:  Evan A Stein; Donald M Black
Journal:  Curr Atheroscler Rep       Date:  2002-01       Impact factor: 5.113

3.  Evaluation and management of atherogenic dyslipidemia: beyond low-density lipoprotein cholesterol.

Authors:  J P Després; I Lemieux; G R Dagenais; B Cantin; B Lamarche
Journal:  CMAJ       Date:  2001-11-13       Impact factor: 8.262

4.  A genomewide search using an original pairwise sampling approach for large genealogies identifies a new locus for total and low-density lipoprotein cholesterol in two genetically differentiated isolates of Sardinia.

Authors:  Mario Falchi; Paola Forabosco; Evelina Mocci; Cesare Cappio Borlino; Andrea Picciau; Emanuela Virdis; Ivana Persico; Debora Parracciani; Andrea Angius; Mario Pirastu
Journal:  Am J Hum Genet       Date:  2004-10-11       Impact factor: 11.025

5.  Lipoproteins: When size really matters.

Authors:  J Bruce German; Jennifer T Smilowitz; Angela M Zivkovic
Journal:  Curr Opin Colloid Interface Sci       Date:  2006-06       Impact factor: 6.448

6.  The hypertriglyceridemic-waist phenotype and the risk of coronary artery disease: results from the EPIC-Norfolk prospective population study.

Authors:  Benoit J Arsenault; Isabelle Lemieux; Jean-Pierre Després; Nicholas J Wareham; John J P Kastelein; Kay-Tee Khaw; S Matthijs Boekholdt
Journal:  CMAJ       Date:  2010-07-19       Impact factor: 8.262

7.  Canadian Cardiovascular Society position statement--recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease.

Authors:  Ruth McPherson; Jiri Frohlich; George Fodor; Jacques Genest
Journal:  Can J Cardiol       Date:  2006-09       Impact factor: 5.223

8.  Sonographic fatty liver, overweight and ischemic heart disease.

Authors:  Yu-Cheng Lin; Huey-Ming Lo; Jong-Dar Chen
Journal:  World J Gastroenterol       Date:  2005-08-21       Impact factor: 5.742

9.  The Quebec Heart Institute: 50 years of excellence in cardiology.

Authors:  Gilles R Dagenais; François Philippon; Jean-Pierre Després; Jean G Dumesnil; Paul Cartier; Peter M Bogaty; Michel Lemieux; André Moisan
Journal:  Can J Cardiol       Date:  2007-10       Impact factor: 5.223

10.  Implications of plasma concentrations of adiponectin in patients with coronary artery disease.

Authors:  Y Nakamura; K Shimada; D Fukuda; Y Shimada; S Ehara; M Hirose; T Kataoka; K Kamimori; S Shimodozono; Y Kobayashi; M Yoshiyama; K Takeuchi; J Yoshikawa
Journal:  Heart       Date:  2004-05       Impact factor: 5.994

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.